InvestorsHub Logo
Followers 789
Posts 118230
Boards Moderated 17
Alias Born 09/05/2002

Re: None

Tuesday, 05/30/2023 10:51:39 AM

Tuesday, May 30, 2023 10:51:39 AM

Post# of 1161
Repotrectinib NDA has 11/27/23 PDUFA date—(with FDA priority review):

The indication is locally advanced or metastatic ROS1-positive NSCLC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News